Thermo Fisher Announces Plan To Pay For Qiagen; Bernard Confirmed As Qiagen CEO
Thermo Fisher has priced an offering of $2.2bn senior notes to pay for its planned acquisition of Qiagen. The news comes the same week, Qiagen confirmed Thierry Bernard as permanent CEO following the departure of former leader Peer Schatz.
You may also be interested in...
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
Belgian start-up miDiagnostics has closed a €14m investment round to accelerate development of its silicon-chip-based diagnostics platform. The company believes the blood analyzer could deliver rapid test results in multiple settings.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.